Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

SGHT
Sight Sciences, Inc. Common Stock
stock NASDAQ

Market Open
Aug 6, 2026 12:38:23 PM EDT
7.17USD+28.495%(+1.59)512,770
7.14Bid   7.18Ask   0.04Spread
Pre-market
Aug 6, 2026 9:25:30 AM EDT
5.45USD-2.330%(-0.13)2,370
After-hours
Aug 5, 2026 4:57:30 PM EDT
5.09USD-8.699%(-0.49)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 10, 2022
05:54AM EST  Sight Sciences Sees Q4 Sales $14.5M-$14.8M Vs. $13.7M Est., Sees FY21 Sales $48.8M-$49.1M Vs. $47.93M Est.   Benzinga
05:50AM EST  Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients lives, today announced preliminary unaudited financial results for the fourth quarter and year ended December 31, 2021.   GlobeNewswire Inc
Jan 7, 2022
01:07PM EST  Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022   Benzinga
01:01PM EST  Morgan Stanley Upgrades Sight Sciences to Overweight, Lowers Price Target to $27   Benzinga
Jan 5, 2022
11:07AM EST  Stocks That Hit 52-Week Lows On Wednesday   Benzinga
Dec 22, 2021
12:30PM EST  FDA Approves Sight Sciences' TearCare System For Common Eye Condition   Benzinga
08:03AM EST  Sight Sciences Reports Received FDA 510(k) Clearance Of TearCare System For Treatment Of Meibomian Gland Dysfunction   Benzinga
08:00AM EST  Sight Sciences Receives FDA 510(k) Clearance of the   GlobeNewswire Inc
Nov 18, 2021
04:05PM EST  Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients lives, today announced plans to participate in the upcoming Piper Sandler Annual Virtual Healthcare Conference.   GlobeNewswire Inc
Nov 17, 2021
08:23AM EST  Sight Sciences Highlights Publication In 'Clinical Ophthalmology' Data Showing Microinvasive Glaucoma Surgery Using Co.'s OMNI Surgical System   Benzinga
08:00AM EST  Microinvasive Glaucoma Surgery with the OMNI Surgical   GlobeNewswire Inc
Nov 11, 2021
08:03AM EST  The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts   Benzinga
07:25AM EST  FDA Clears Sight Sciences' Trial Of Canaloplasty Combined With Cataract Surgery To Lower Ocular Pressure   Benzinga
Nov 10, 2021
04:38PM EST  Sight Sciences Reports FDA Authorization For PRECISION Trial Of Canal Viscodilation In Combo With Cataract Surgery   Benzinga
04:09AM EST  Earnings Scheduled For November 10, 2021   Benzinga
Oct 27, 2021
04:05PM EDT  Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the quarter ended September 30, 2021 after the market close on Wednesday, November 10, 2021. The companys management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.   GlobeNewswire Inc
Oct 23, 2021
02:42PM EDT  Last Week's Notable Insider Buys: Navitas Semiconductor, Truist Financial And More   Benzinga
Oct 21, 2021
12:11PM EDT  3 Stocks Insiders Are Buying   Benzinga
Oct 20, 2021
08:12AM EDT  Sight Sciences Highlights Publication Of TearCare Clinical Data In Cornea   Benzinga
08:00AM EDT  Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on addressing the underlying causes of the world's most prevalent eye diseases, today announced publication in the journal Cornea of positive results from OLYMPIA, a multicenter, investigator-masked, randomized controlled trial.   GlobeNewswire Inc
Oct 12, 2021
08:13AM EDT  The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology   Benzinga
Sep 29, 2021
08:13AM EDT  The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug   Benzinga
Sep 22, 2021
07:45AM EDT  The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs   Benzinga
Sep 21, 2021
08:20AM EDT  The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data   Benzinga
Sep 17, 2021
07:36AM EDT  The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold   Benzinga
Sep 16, 2021
06:29PM EDT  Sight Sciences, Inc. (NASDAQ: SGHT) today announced that it filed a lawsuit in the United States District Court in Delaware against Ivantis, Inc. for infringement of U.S. Patent Numbers 8,287,482, 9,370,443, 9,486,361, and 10,314,742. These patents describe and claim devices and methods for reducing intraocular pressure in the eye.   GlobeNewswire Inc
Aug 26, 2021
04:05PM EDT  Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on developing and commercializing devices designed to address the underlying causes of the world's most prevalent eye diseases, today announced plans to participate in the upcoming virtual Morgan Stanley Global Healthcare Conference.   GlobeNewswire Inc
Aug 24, 2021
08:00AM EDT  Sight Sciences, Pioneering the Development of the Standalone MIGS   GlobeNewswire Inc
Aug 12, 2021
05:21PM EDT  Viant Technology Sees FY21 Sales $205M-$210M   Benzinga
05:19PM EDT  Sight Sciences Q2 Sales $12.5M, Up 258% YoY   Benzinga
04:05PM EDT  Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of care and improve patients lives, today reported financial results for the quarter ended June 30, 2021.   GlobeNewswire Inc
Aug 9, 2021
11:07AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
10:24AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2021   Benzinga
09:47AM EDT  B of A Securities Initiates Coverage On Sight Sciences with Buy Rating, Announces Price Target of $45   Benzinga
08:26AM EDT  Citigroup Initiates Coverage On Sight Sciences with Buy Rating, Announces Price Target of $46   Benzinga
06:06AM EDT  Morgan Stanley Initiates Coverage On Sight Sciences with Equal-Weight Rating, Announces Price Target of $41   Benzinga
05:10AM EDT  Piper Sandler Initiates Coverage On Sight Sciences with Overweight Rating, Announces Price Target of $44   Benzinga
Aug 8, 2021
10:11AM EDT  The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight   Benzinga
Aug 3, 2021
07:55AM EDT  The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business   Benzinga
Aug 2, 2021
04:34PM EDT  Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the second quarter 2021 after the market close on Thursday, August 12, 2021. The companys management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.   GlobeNewswire Inc
Jul 27, 2021
11:13AM EDT  The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts   Benzinga
Jul 23, 2021
07:45AM EDT  The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs   Benzinga
Jul 19, 2021
05:23PM EDT  Sight Sciences Announces Closing of Initial Public Offering and   GlobeNewswire Inc
Jul 15, 2021
12:50PM EDT  Sight Sciences Shares Open For Trade At $30; IPO Priced At $24/Share   Benzinga
09:23AM EDT  Sight Sciences Shares Will Open For Quote At 10:35 a.m. EDT, Expected To Open For Trade After 10:45 a.m. EDT; IPO Priced At $24/Share   Benzinga
Jul 14, 2021
09:12PM EDT  Sight Sciences Prices IPO Of 10 Mln Shares At $24.00/shr   RTTNews
06:54PM EDT  Sight Sciences Announces Pricing of Initial Public Offering   GlobeNewswire Inc
11:21AM EDT  IPO Previews For The Week   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2026 ChartExchange LLC